Related Experiment Video
Updated: Jan 19, 2026

Porcine As a Training Module for Head and Neck Microvascular Reconstruction
Published on: September 29, 2018
Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers
Juanjuan Hu1, Caiying Jiang2, Meijun Zheng1
1Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University Chengdu, Sichuan, P. R. China.
Abstract:
Head and neck cancers (HNCs) are the sixth most common type of cancer in the world. Despite the development of refined surgical techniques and precise targeted radiation, patients with HNCs have a dismal prognosis. Here, we examine the expression profile of B7-H3 in HNCs and verify whether B7-H3 can serve as a novel therapeutic target for HNCs via anti-B7-H3×CD3 bispecific antibodies (biAbs). We analyzed the expression level of B7-H3 in 274 HNC samples and evaluated the association between B7-H3 expression and clinicopathological parameters. Anti-B7-H3×CD3 biAbs were constructed, and the efficacy of these biAbs in targeting HNCs was assessed in vitro and in vivo. As a result, high expression of B7-H3 was detected in 66.1% of clinical HNC samples and was correlated with poor survival. Specific antitumor effects of anti-B7-H3×CD3 biAbs were confirmed in vitro using HNC cell lines. In xenograft HNC mouse model, anti-B7-H3×CD3 biAbs delayed tumor growth and prolonged survival. In conclusion, B7-H3 is frequently overexpressed in HNCs and could be a promising therapeutic target for biAb therapy.
Insights
B7-H3 is highly expressed in most head and neck cancers (HNCs), correlating with poor survival. Novel bispecific antibodies targeting B7-H3 show promise for treating HNCs by inhibiting tumor growth and improving survival.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Biology
Background:
- Head and neck cancers (HNCs) represent a significant global health burden with poor prognoses despite current treatments.
- B7-H3 is an immune checkpoint molecule whose role in HNCs requires further investigation as a potential therapeutic target.
Purpose of the Study:
- To investigate the expression profile of B7-H3 in head and neck cancers.
- To evaluate B7-H3 as a potential therapeutic target for HNCs using anti-B7-H3×CD3 bispecific antibodies (biAbs).
Main Methods:
- Analysis of B7-H3 expression in 274 clinical HNC samples and correlation with clinicopathological parameters.
- Construction and in vitro/in vivo assessment of anti-B7-H3×CD3 biAbs efficacy against HNC cell lines and xenograft models.
Main Results:
- High B7-H3 expression was detected in 66.1% of HNC samples, significantly associated with poorer patient survival.
- Anti-B7-H3×CD3 biAbs demonstrated specific antitumor effects in vitro and significantly delayed tumor growth and prolonged survival in vivo.
Conclusions:
- B7-H3 is frequently overexpressed in head and neck cancers and serves as a viable therapeutic target.
- Anti-B7-H3×CD3 bispecific antibody therapy shows potential as a novel treatment strategy for HNCs.
Related Concept Videos
07:43Porcine As a Training Module for Head and Neck Microvascular Reconstruction
Targeted Cancer Therapies
There are several types of targeted therapies against...
08:59A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...

